Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination of econazole nitrate and benzydamine hydrochloride is formulated as a vaginal pessary for the treatment of vulvovaginal candidiasis and associated symptoms. Econazole nitrate is an imidazole antifungal agent that inhibits lanosterol 14-α demethylase, disrupting ergosterol synthesis in fungal cell membranes, leading to increased permeability and cell death. Benzydamine hydrochloride is a non-steroidal anti-inflammatory drug (NSAID) with local anesthetic, analgesic, anti-inflammatory, and membrane-stabilizing properties; it acts by inhibiting pro-inflammatory cytokines and stabilizing cellular membranes. The combination aims to provide both antifungal efficacy (from econazole) and rapid symptomatic relief (from benzydamine). Systemic absorption from intravaginal administration is low[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on econazole nitrate + benzydamine hydrochloride.